Effect of Clazosentan in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Cerebral vasospasm is the most important potentially treatable cause of mortality and morbidity following aneurysmal subarachnoid hemorrhage (aSAH). Clazosentan, a selective endothelinreceptor antagonist, has been suggested to help reduce the incidence of vasospasm in patients with aSAH....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiang, Li, Yi-Ming, Li, Wei-Qing, Huang, Cheng-Guang, Lu, Yi-Cheng, Hou, Li-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474756/
https://www.ncbi.nlm.nih.gov/pubmed/23082215
http://dx.doi.org/10.1371/journal.pone.0047778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474756/
https://www.ncbi.nlm.nih.gov/pubmed/23082215
http://dx.doi.org/10.1371/journal.pone.0047778

Ejemplares similares